Retatrutide
Price range: £90.00 through £155.00
CAS NUMBER: 2381089-83-2
Strengths Available: 30mg/40mg /60mg
Format: Sealed containment / vial presentations available
Volume: 3mL
What Retatrutide is about?
It is Advanced Triple-Pathway Metabolic Research Peptide. Retatrutide is used as a research tool to study complex metabolic signalling involving appetite regulation, energy balance, and hormone pathway interaction. It is not supplied for therapeutic use.
It combines three major metabolic pathways into
one molecule, allowing researchers to explore whole‑system metabolic responses rather than isolated receptor effects.
Description
What is Retatrutide?
Retatrutide is a synthetic peptide designed to activate three key
hormone receptors involved in metabolism: GLP‐1, GIP, and
glucagon receptors. In simple terms, it allows researchers to
observe how hunger signals, energy use, and metabolic responses
interact together rather than in isolation.
This multi‐pathway design is the primary reason Retatrutide is
considered a valuable research tool in advanced metabolic and
endocrine studies.
Why Retatrutide Attracted Research Interest
As researchers continue to explore the complex biology of metabolism, energy balance, body composition, and glucose regulation, Retatrutide has emerged as a particularly promising area of investigation. Unlike earlier peptide compounds that primarily target a single biological pathway, Retatrutide has attracted attention for its interaction with three distinct metabolic receptor pathways—GLP-1 (Glucagon-Like Peptide-1), GIP (Glucose-Dependent Insulinotropic Polypeptide), and glucagon receptors.
This multi-receptor approach has positioned Retatrutide as an important compound in laboratory studies investigating how multiple metabolic signalling pathways may work together to regulate energy utilisation, nutrient metabolism, and physiological homeostasis.
The growing scientific interest surrounding Retatrutide reflects the broader effort to better understand the interconnected mechanisms that influence metabolic function, body composition, and cellular energy regulation. As research continues to evolve, Retatrutide remains at the forefront of experimental studies exploring next-generation metabolic peptides.
Areas commonly investigated include:
- Triple‐pathway metabolic signalling research
- Advanced appetite and satiety modelling
- Energy expenditure and metabolic flexibility studies
- Comparative research versus GLP‐1‐only and dual‐agonist
compounds - Whole‐system metabolic response analysis
Scientific Background and Research Context
Modern metabolic research continues to focus on understanding the complex biological systems that regulate energy balance, nutrient utilisation, and body composition. Among the compounds receiving increasing scientific attention is Retatrutide, an investigational peptide studied for its interaction with multiple metabolic signalling pathways.
Unlike traditional single-pathway compounds, Retatrutide has been investigated for its activity across three key receptor systems—GLP-1 (Glucagon-Like Peptide-1), GIP (Glucose-Dependent Insulinotropic Polypeptide), and glucagon receptors. Researchers are examining how simultaneous activation of these pathways may influence metabolic regulation, energy expenditure, appetite signalling, and nutrient metabolism within controlled laboratory models.
Scientific interest in Retatrutide stems from the growing recognition that metabolism is governed by multiple interconnected biological processes rather than a single pathway. By studying compounds that engage several receptor systems simultaneously, researchers aim to gain a deeper understanding of the complex mechanisms involved in metabolic function and cellular energy regulation.
As metabolic science continues to advance, Retatrutide has become an important investigational compound across academic institutions, biotechnology organisations, and pharmaceutical research programmes. Ongoing laboratory studies continue to explore its role in expanding scientific knowledge of metabolic signalling, body composition, and the biological pathways that contribute to overall metabolic homeostasis.
Although research remains ongoing, Retatrutide represents one of the most closely studied next-generation metabolic peptides within contemporary bioscience, contributing to a broader understanding of how integrated receptor signalling may influence metabolic physiology.
What the Research Has Shown
Why Researchers Are Paying Attention to Retatrutide
Published research includes extensive preclinical work and late‐stage clinical investigations examining body‐weight change, metabolic biomarkers, and tolerability profiles. These
studies report significant biological activity within controlled research settings, helping explain the molecule’s prominence in metabolic research.
It is important to understand that such findings arise from structured experimental environments with defined protocols, monitoring, and eligibility criteria. Within the Freshstart catalogue, Retatrutide is supplied strictly as a research material and is not positioned as a therapeutic product.
Ingredient Profile
Single research compound: Retatrutide
CAS: 2381089-83-2
Purity >99%
Supplied as lyophilised powder (no excipients, fillers or additives).
Active Ingredients
Retatrutide — 10/ 20/ 30 / 40 / 60mg
Ingredient Breakdown
Retatrutide: 30 / 40 / 60mg of active peptide per vial (lyophilised).
What is Retatrutide used for in research?
Retatrutide is used as a research tool to study complex metabolic signalling involving appetite
regulation, energy balance, and hormone pathway
interaction. It is not supplied for therapeutic use.
Why does Retatrutide receive more attention than many other peptides?
Because it combines three major metabolic pathways into one molecule, allowing researchers to explore whole‑system metabolic responses rather than isolated receptor effects.
Is Retatrutide a medicine?
No. Although it has been investigated in clinical research settings, Retatrutide is supplied by freshstart strictly as a research material and no medical claims are made.
What strengths and formats are available?
Retatrutide is available as 24 mg and 40 mg in sealed containment devices and/or vials, and as a 60 mg vial‑only format. Availability is confirmed at batch level.
Why is the 60 mg format vial only?
Higher‑concentration formats are better suited to vial‑based analytical workflows using calibrated laboratory instruments, which offer greater flexibility for advanced research protocols.
Is the product supplied pre‑mixed or lyophilised?
Depending on the batch, Retatrutide may be supplied as a pre‑mixed solution or as a lyophilised powder. This is clearly stated on the certificate of analysis.
Do you provide certificates of analysis (COAs)?
Yes. Every batch is supplied with a COA confirming identity, purity metrics, and batch traceability.
What purity standard does Freshstartpharma work to?
Freshstart supplies high‑purity, research‑grade materials. Exact purity values are batch‑specific and are detailed on the COA.
Can Retatrutide be supplied internationally?
Yes. Freshstart Pharma supports international research projects across multiple regions, including temperature‑controlled and cold‑chain shipping where required.
Is this document an instruction for use?
No. This document is a product information page for research cataloguing purposes only and does not provide usage or administration instructions.
How should researchers verify batch specifics?
Researchers should refer to the COA and batch documentation supplied with the product for confirmation of identity, presentation, and analytical data.
Research & laboratory use only. Not for human or veterinary use. Not a medicinal product, supplement, food or medical device. No therapeutic, diagnostic, cosmetic, wellness or lifestyle claims are made or implied. Analytical reference/click information is a laboratory measurement aid only and must not be applied to living systems.
Typically supplied at >99% purity, supported by batch-specific analytical data. UK-based preparation, analysis and release under scientist-led, GMP-aligned processes with full batch-level traceability. Certificate of Analysis (CoA) available on request; independent analytical verification where appropriate.
Store the lyophilised powder refrigerated at 2–8°C, protected from light and moisture; suitable for longer-term storage frozen at -20°C. Handle under appropriate laboratory conditions. For in vitro research use only.
For in vitro laboratory research only. Reconstitution, handling and experimental design at the discretion of the qualified researcher. The 300-click sealed-containment system is an analytical measurement reference only and does not represent dosing or administration guidance. Not for use in living systems.
Partner with FreshstartPharma– Where Accuracy Meets Innovation
Freshstartpharma is committed to delivering high-quality research-grade products designed for advanced scientific applications. We offer wholesale partnerships to selected businesses that share our values of integrity, quality, and innovation. Whether you’re an established distributor or an emerging research supply company, we invite you to join our network and benefit from exclusive access to our state-of-the-art product range.
Related Products
Tirzepatide
Glow 70 (BPC-157/TB-500/GHK-Cu)
DSIP
